CSIMarket
 
Halozyme Therapeutics Inc   (HALO)
Other Ticker:  
 
 
Price: $40.8600 $0.07 0.172%
Day's High: $41.48 Week Perf: -0.83 %
Day's Low: $ 40.56 30 Day Perf: 16.54 %
Volume (M): 1,827 52 Wk High: $ 45.00
Volume (M$): $ 74,639 52 Wk Avg: $37.39
Open: $40.56 52 Wk Low: $29.85



 Market Capitalization (Millions $) 5,479
 Shares Outstanding (Millions) 134
 Employees 3,011
 Revenues (TTM) (Millions $) 829
 Net Income (TTM) (Millions $) 282
 Cash Flow (TTM) (Millions $) -116
 Capital Exp. (TTM) (Millions $) 17

Halozyme Therapeutics Inc
Halozyme Therapeutics Inc.
is a biotechnology company based in San Diego, California, whose mission is to develop and commercialize innovative therapies for the treatment of cancer and other chronic diseases.
Founded in 1998, the company is focused on creating novel pharmaceutical products that are designed to improve the lives of patients using its proprietary Enhanze drug delivery technology.
The company has established strategic collaborations with some of the world's leading pharmaceutical companies, including Roche, Pfizer, and Bristol-Myers Squibb.
The company's Enhanze technology platform is based on the use of an enzyme called hyaluronidase, which is designed to break down the extracellular matrix that surrounds tumor cells and other tissues, thereby allowing drugs to diffuse more easily into the target cells.
This approach has been shown to enhance the pharmacokinetics and therapeutic efficacy of a variety of drugs, including monoclonal antibodies and chemotherapy agents.
Halozyme Therapeutics has a robust pipeline of drug candidates that utilize this technology, including several clinical-stage products that are being evaluated in various oncology indications.
One of the company's most promising pipeline candidates is PEGPH20, a recombinant human hyaluronidase enzyme that is being developed for the treatment of pancreatic cancer.
PEGPH20 is currently in Phase III clinical trials, and the company is hoping to demonstrate that it can improve the outcomes for this notoriously difficult-to-treat disease.
In addition to its Enhanze platform, Halozyme Therapeutics is also involved in the development of other novel therapies, including immune-oncology agents and enzyme replacement therapies for rare diseases.
The company has a diverse intellectual property portfolio, with more than 400 issued patents and pending patent applications worldwide.
Overall, Halozyme Therapeutics Inc.
is a leading biotech company that is leveraging its innovative technology platform to develop new and exciting treatments for some of the most challenging diseases facing patients today.
The company has a strong track record of success, having brought several products to market already, and it seems poised to continue to be a major player in the biotech industry in the years to come.


   Company Address: 12390 El Camino Real San Diego 92130 CA
   Company Phone Number: 794-8889   Stock Exchange / Ticker: NASDAQ HALO
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Halozyme Therapeutics Inc

Halozyme Therapeutics Inc. Reports Strong Financial Results, with Profits Up 55% and Revenue Surging 26.7% in Q4 2023

Halozyme Therapeutics Inc. experienced a decline in stock price by 5.37% during February 2024, bringing the share price to -3.73% in the past 90 days. Additionally, the stock is currently trading only 20.9% above its 52-week low. However, looking at the financial results released by the company, it is evident that there have been some positive developments in terms of profits and revenues.
In the fourth quarter and full year of 2023, Halozyme reported significant improvements in its financial performance. Profits jumped by 55.17% year on year to $0.66 per share, and revenue increased by 26.746% to $230.04 million. These numbers showcase a remarkable growth trajectory for the company, especially when compared to its peers in the Biotechnology & Pharmaceuticals sector.

Halozyme Therapeutics Inc

Halozyme Therapeutics Inc Defies Industry Contraction with Surprising 3.377% Revenue Increase in Q3 2023

Halozyme Therapeutics Inc, a biotechnology and pharmaceuticals company, has surprised many with its strong performance in the July to September 30, 2023 interval. The company's profit per share surged by 38.64% to reach $0.61 per share, while revenue saw a 3.377% increase to $216.03 million compared to the same quarter a year ago.
This growth is particularly noteworthy given the overall contraction of -11.52% in the biotechnology and pharmaceuticals industry. Halozyme Therapeutics Inc has managed to buck the trend and demonstrate positive revenue growth.

Halozyme Therapeutics Inc

Halozyme Therapeutics Inc Defies Industry Downturn, Posts Remarkable 250% Increase in Profits

In the midst of a struggling Biotechnology & Pharmaceuticals sector, Halozyme Therapeutics Inc appears to have defied the odds and thrived in the second quarter of 2023. The company witnessed an astounding growth in net profit per share, which surged by a staggering 250% to $0.56, compared to the previous year. This surge is primarily attributed to the company's growing revenue, which increased by an impressive 45.071% to $221.04 million.
While many companies within the sector have been grappling with receding businesses and declining revenues, Halozyme Therapeutics Inc has managed to buck the trend. In the previous reporting season, the company reported a revenue of $162.14 million and net earnings of $0.29 per share. The financial period ending June 30, 2023 witnessed a substantial increase in net earnings, with profits soaring to $74.754 million, representing a remarkable growth of 229.53% compared to the same period a year ago.

Halozyme Therapeutics Inc

Surprising Decline in Earnings and Net Income Raise Concerns for Halozyme Therapeutics Inc in Q1 2023

Investors should brace themselves for a bearish season ahead as Halozyme Therapeutics Inc, a biotechnology and pharmaceuticals company, announced its first quarter results for 2023, which showed a decrease in earnings per share (EPS) and net income, albeit with an improvement in the return on equity (ROE).
Although Halozyme Therapeutics Inc's ROE of 116.1% in Q1 2023 exceeded its average ROE,
it is worth noting that two other companies in the same industry had a higher ROE. Moreover, the company's net income was on a decline, which raises alarming concerns for investors. The report showed that the company recorded EPS of $0.29 and revenue of $181.50 million in the Q1 of 2023, compared to an EPS of $0.43 in Q1 2022.






 

Halozyme Therapeutics Inc's Segments
 
 
• View Complete Report
  Company Estimates  
  Revenue Outlook
Halozyme Therapeutics Inc does not provide revenue guidance.

Earnings Outlook
Halozyme Therapeutics Inc does not provide earnings estimates.

 
Geographic Revenue Dispersion




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com